MDLinx E-mail Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 emails at a time.


* From Email: 
* To Email: 
To Email: 
To Email: 
To Email: 
To Email: 
Email Subject Line: 
Comments:

Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation

Musumeci G et al. – In DES–treated patients on prolonged dual antiplatelet therapy (DAPT), major bleeding occurring at 1 year and up to 4 years following drug–eluting stent (DES) implantation in patients on prolonged DAPT is associated with poor long–term prognosis.

Methods
  • A total of 1,437 patients undergoing DES implantation discharged on DAPT with aspirin and clopidogrel for 1 year were studied.
  • Patients were followed for up to 4 years (34.3 ± 14.4 months) and the prevalence and predictors of in–hospital and long–term thrombolysis in myocardial infarction (TIMI) major and minor bleeding events evaluated.
  • The impact of bleeding events on major adverse cardiac events (MACE), overall death, and stent thrombosis (ST) was also assessed.

Results
  • The incidences of 30 days major and minor bleeding were 1.3 and 3.3%, respectively.
  • The incidences of 1–year major and minor bleeding were 3.0 and 5.6%, respectively.
  • The incidences of major and minor bleeding up to 4–year follow–up were 3.6 and 6.9%, respectively.
  • At multivariable analysis, 1–year major bleeding was positively predicted by use of oral anticoagulants at hospital discharge [odds ratio (OR) = 13.4, 95% confidence interval (CI) 3.0–59.2, P = 0.001], anemia at admission (OR = 6.7, 95% CI = 2.7–16.5, P < 0.001) and use of glycoprotein IIb/IIIa inhibitors (OR = 2.7, 95% CI = 1.1–6.5, P = 0.03) and negatively predicted by male gender (OR = 0.39, 95% CI = 0.16–0.97, P = 0.042).
  • Overall, major bleeding at 1 year and at long–term follow–up was associated with an increased risk of MACE, cardiac death and ST.
  • Patients who had any bleeding event were more likely to prematurely discontinue antiplatelet therapy (50% vs. 9.6%, P < 0.001).
[more...]

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close